ERR2208959
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- WNT_BETA_CATENIN_SIGNALING+0.400
- ANGIOGENESIS+0.300
- HYPOXIA+0.300
- TGF_BETA_SIGNALING+0.300
- UV_RESPONSE_DN+0.300
- COAGULATION+0.200
- ESTROGEN_RESPONSE_EARLY+0.200
- HEDGEHOG_SIGNALING+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- MTORC1_SIGNALING-0.400
- MYC_TARGETS_V1-0.400
- IL6_JAK_STAT3_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- COMPLEMENT-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613703 | — | D | 0.800 |
| 2 | X9d79253b.8c45.4bde.a42d.c399fb107400 | — | cohortMD2 | 0.799 |
| 3 | SRR26320067 | — | — | 0.793 |
| 4 | GSM5359429 | — | — | 0.790 |
| 5 | 20040084.LumA | — | A | 0.785 |
| 6 | R302 | — | — | 0.782 |
| 7 | TCGA-BH-A0H6-01A-21R-A056-07 | — | A | 0.779 |
| 8 | TCGA-CV-7103-01A-21R-2016-07 | — | — | 0.777 |
| 9 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.773 |
| 10 | TCGA-CV-5976-01A-11R-1686-07 | — | — | 0.768 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.600 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |